Raymond James & Associates Takes Position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Raymond James & Associates Takes Position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Raymond James & Associates acquired a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 17,499 shares of the medical research company's stock, valued at approximately $27,000.
雷蒙德·詹姆斯 & 同事在加速診斷公司獲得了一個新的位置, 公司. (NASDAQ: AXDX — 獲得評級) 根據其最近與證券交易委員會提交的文件 (美國證券交易委員會).該公司收購了該醫學研究公司股票的 17,499 股，價值約為 27,000 美元。
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AXDX. Bank of Montreal Can acquired a new stake in shares of Accelerate Diagnostics during the 1st quarter worth approximately $27,000. UBS Group AG grew its holdings in Accelerate Diagnostics by 1,004.2% during the 2nd quarter. UBS Group AG now owns 43,593 shares of the medical research company's stock worth $44,000 after acquiring an additional 39,645 shares during the period. HighTower Advisors LLC raised its position in shares of Accelerate Diagnostics by 115.6% during the 1st quarter. HighTower Advisors LLC now owns 37,302 shares of the medical research company's stock valued at $53,000 after acquiring an additional 20,000 shares during the last quarter. Chartist Inc. CA bought a new stake in shares of Accelerate Diagnostics during the 2nd quarter valued at $65,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Accelerate Diagnostics by 102.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 90,280 shares of the medical research company's stock valued at $90,000 after purchasing an additional 45,731 shares during the period. 33.14% of the stock is currently owned by institutional investors and hedge funds.
一些其他對沖基金和其他機構投資者最近也增加或減少了他們在 AXDX 的股份。蒙特利爾銀行可以在第一季度收購了加速診斷股份的新股份，價值約為 27,000 美元。瑞銀集團股份公司在第二季度增加了 1,004.2％ 的加速診斷。瑞銀集團股份有限公司現時擁有該醫學研究公司股票 43,593 股，價值 44,000 美元。HighTower 顧問有限責任公司在第一季度提高了其在加速診斷股份的地位 115.6％。HighTower 顧問有限責任公司現在擁有 37,302 股的醫學研究公司的股票價值為 $53,000 在上個季度額外收購 20,000 股之後。Chartist 公司 CA 在第二季度購買了加速診斷股份的新股份，價值為 65,000 美元。最後, 價格 T 羅威協會公司. MD 在第二季度提升了其在加速診斷股份的股份 102.7%.T 羅威聯營股份有限公司現在擁有 90,280 股價值 90,000 美元的醫學研究公司股票，價值在此期間額外購買了 45,731 股。33.14％ 的股票目前由機構投資者和對沖基金擁有。
Wall Street Analysts Forecast Growth
華爾街分析師預測增長
Separately, StockNews.com raised Accelerate Diagnostics from a "sell" rating to a "hold" rating in a research note on Thursday, February 2nd.
另外，Stocknews.com 在 2 月 2 日（星期四）的研究報告中將加速診斷從「賣出」評級提高到「暫停」評級。
Accelerate Diagnostics Stock Performance
加速診斷庫存效能
Accelerate Diagnostics (NASDAQ:AXDX – Get Rating) last released its quarterly earnings data on Monday, November 14th. The medical research company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. The firm had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.50 million. On average, sell-side analysts forecast that Accelerate Diagnostics, Inc. will post -0.86 earnings per share for the current year.
加速診斷 (NASDAQ: AXDX — 取得評分) 上次公佈其季度收益資料 (週一, 11 月 14 日 (星期一)。這家醫學研究公司報告了本季度每股收益（0.18 美元），超過了分析師的共識估計（0.21 美元）0.03 美元。該公司在本季度的收入為 2.96 萬美元，而共識估計為 350 萬美元。平均而言，賣方分析師預測，加速診斷公司將在本年度公佈 -0.86 的每股收益。
Accelerate Diagnostics Profile
加速診斷設定檔
(Get Rating)
(取得評分)
Accelerate Diagnostics, Inc is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.
加速診斷, Inc 是一家體外診斷公司，致力於提供解決方案，透過快速診斷嚴重感染來改善患者療效並降低醫療保健成本。它還專注於開發和商業化創新儀器，用於傳染病原體的快速識別和抗生素易感性測試。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Accelerate Diagnostics (AXDX)
- CVS Health Corporation Is Coiled And Ready To Spring Higher
- Will The Pullback In Paycom Payoff For Investors?
- TJX Among Apparel Retailers All Dressed Up & Ready For Growth
- Daqo New Energy Charged Up For New Highs
- No Spice In Chipotle Results, Is Now The Time To Buy?
- 免費取得有關加速診斷 (AXDX) 的研究報告
- CVS 健康公司捲繞並準備好升高
- 將回調在 Paycom 回報投資者?
- TJX 在服裝零售商中全部打扮並為增長做好準備
- 大全新能源增加了新高
- Chipotle 結果中沒有香料，現在是時候購買了嗎？
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Rating).
想看看還有哪些對沖基金持有 AXDX？ 訪問 Holdingschannel.com 以獲取有關加速診斷公司（NASDAQ：AXDX-獲得評分）的最新 13 樓文件和內部交易。
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
接收每日加速診斷的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關加速診斷和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。